Taysha Gene Therapies, Inc.
TSHA Nasdaq
SEC CIK 1806310
Follow Taysha Gene Therapies
Weekly email: filings, results
Revenue, last quarter
$0
Net income
−$39.1M
−19.5% vs same quarter last year
EPS, diluted
−$0.10
−11.1% vs same quarter last year
Operating cash flow
−$32.9M
−36.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $9.8M | −$109M |
| FY24 | $8.3M | −$89.3M |
| FY23 | $15.5M | −$111.6M |
| FY22 | $2.5M | −$166M |
| FY21 | - | −$174.5M |
| FY20 | - | −$60M |
| FY19 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1130.6% | −1115.3% |
| FY24 | −1097.6% | −1071.6% |
| FY23 | −468.8% | −722.1% |
| FY22 | −6492.7% | −6635.3% |
| FY21 | - | - |
| FY20 | - | - |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$93.8M |
| FY24 | −$81.6M |
| FY23 | −$76.9M |
| FY22 | −$109M |
| FY21 | −$132.3M |
| FY20 | −$30.8M |
| FY19 | - |
- Taysha Gene Therapies
- Healthcare median
Show the numbers
| Year | Taysha Gene Therapies | Healthcare median |
|---|---|---|
| FY25 | −1115.3% | −30.6% |
| FY24 | −1071.6% | −47% |
| FY23 | −722.1% | −58% |
| FY22 | −6635.3% | −80.4% |
| FY21 | - | −71.8% |
| FY20 | - | −62.2% |
| FY19 | - | −46.2% |